Table 3.
Prevalence of metabolic syndrome among the study population
| Age groups (years) |
Revised ATP III criteria | IDF criteria | CDS criteria | ||||||
| Men (n=716) |
Women (n=1005) |
Total (n=1721) |
Men (n=716) |
Women (n=1005) |
Total (n=1721) |
Men (n=716) |
Women (n=1005) |
Total (n=1721) |
|
| 20~ | 20.90 | 14.50 | 17.78* | 7.50 | 11.10 | 9.26* | 0.00 | 0.90 | 0.44* |
| 30~ | 29.90 | 22.10 | 26.04* | 11.90 | 20.10 | 15.96* | 10.00 | 1.70 | 5.89* |
| 40~ | 36.70 | 30.70 | 33.74* | 8.20 | 27.30 | 17.61* | 13.30 | 5.20 | 9.31* |
| 50~ | 29.30 | 40.20 | 34.64* | 8.30 | 38.60 | 23.13* | 18.80 | 16.30 | 17.58* |
| 60~ | 36.10 | 54.30 | 45.30* | 19.30 | 52.20 | 35.93* | 26.10 | 20.30 | 23.17* |
| Overall | 35.5 (32.0–39.0) | 28.3 (25.5–31.0) | 31.6* (29.4–33.8) | 25.2 (22.0–28.3) | 25.4 (22.7–28.1) | 25.3* (23.2–27.3) | 27.9 (24.6–31.2) | 10.9 (9.0–12.9) | 18.7* (16.9–20.6) |
| Overall (standardised) | 30.21† (26.8–33.5) | 31.74† (28.9–34.6) | 30.96‡ (28.8–33.2) | 10.85† (8.6–13.2) | 29.24† (26.4–32.1) | 19.93‡ (18.0–21.8) | 13.12† (10.6–15.6) | 8.58† (7.1–10.6) | 10.88‡ (9.4–12.3) |
Adjustment was conducted using sample survey data from 1% of the population in 2015 by direct methods.
*Sex-adjusted percentages for each age group.
†Age-adjusted percentages for men and women.
‡Age-adjusted and sex-adjusted percentages.
ATP, Adult Treatment Panel.